Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Total Non-Current Liabilities: 2019-2024

Historic Total Non-Current Liabilities for Legend Biotech (LEGN) over the last 6 years, with Dec 2024 value amounting to $352.0 million.

  • Legend Biotech's Total Non-Current Liabilities fell 23.14% to $268.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.1 million, marking a year-over-year decrease of 23.14%. This contributed to the annual value of $352.0 million for FY2024, which is 7.58% down from last year.
  • Legend Biotech's Total Non-Current Liabilities amounted to $352.0 million in FY2024, which was down 7.58% from $380.8 million recorded in FY2023.
  • In the past 5 years, Legend Biotech's Total Non-Current Liabilities ranged from a high of $380.8 million in FY2023 and a low of $8.8 million during FY2020.
  • In the last 3 years, Legend Biotech's Total Non-Current Liabilities had a median value of $352.0 million in 2024 and averaged $340.5 million.
  • In the last 5 years, Legend Biotech's Total Non-Current Liabilities crashed by 96.90% in 2020 and then soared by 1,319.95% in 2021.
  • Yearly analysis of 5 years shows Legend Biotech's Total Non-Current Liabilities stood at $8.8 million in 2020, then spiked by 1,319.95% to $124.3 million in 2021, then skyrocketed by 132.36% to $288.9 million in 2022, then spiked by 31.83% to $380.8 million in 2023, then declined by 7.58% to $352.0 million in 2024.